The US Food and Drug Administration (FDA) has accepted Otsuka Pharmaceutical’s biologics licence application for ...

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgAN) in adults.

To lessen bruising, do not rub the injection site after each dose. Learn how to store and discard medical supplies safely. Patients who are getting immune globulin for the first time, those who ...

The FDA target action date (PDUFA date) is set for November 28, 2025 If approved, sibeprenlimab would offer patients a convenient single-dose prefilled syringe for subcutaneous injection every ...

HYQVIA is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10% and one vial of Recombinant Human Hyaluronidase PH20 ...

"We are very pleased that patients in Japan with agammaglobulinemia or hypogammaglobulinemia can now access HYQVIA, which represents the first and only subcutaneous immunoglobulin therapy that ...

but subcutaneous immunoglobulin bypasses this issue. The CSL-sponsored trial also uses a control injection of the same volume to ensure accuracy, she said. Animal studies from Iwasaki’s lab have ...